This article was updated to include information on the FDA approval of the sNDA for liposomal bupivacaine on April 6.
New York—Researchers seeking to reduce the duration of postoperative pain and opioid consumption in patients undergoing orthopedic surgery recently reported some promising findings: In a phase 3 trial designed to meet FDA standards for approval, investigators demonstrated that liposomal bupivacaine (Exparel, Pacira) administered as a single-injection nerve block